Schrödinger Snapshot
To improve human health and quality of life by transforming the way scientists design therapeutics and materials.
Schrödinger is opening new worlds of possibility for drug discovery and materials design through its industry-leading computational platform which is deployed by pharmaceutical, biotechnology, chemical, and electronics companies to accelerate R&D. The Schrödinger platform revolutionizes discovery by enabling far broader exploration of chemical space and delivers better therapeutic candidates and higher-quality compounds far faster than traditional methods, at a lower cost, and with a higher probability of success. Schrödinger has built a robust pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic.
